Matches in DBpedia 2014 for { <http://dbpedia.org/resource/DOV-216,303> ?p ?o. }
Showing items 1 to 33 of
33
with 100 items per page.
- DOV-216,303 abstract "DOV 216,303 is an antidepressant drug originally developed by DOV Pharmaceutical and now licensed to the larger pharmaceutical company Merck & Co., which is currently in clinical trials. It is a so-called triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is expected to launch sometime around 2011. It is the racemic mixture of DOV 21,947 and its (–)-enantiomer. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively. It is closely related to DOV 102,677 and DOV 21,947, both of which are also being developed in collaboration with Merck. Doses of up to 100mg per day are well tolerated with only nausea, and GI disturbances reported as side effects.This compound does not cause notable shifts in LMA, and is not psychostimulant. The effects are not long-lasting. More recently (see attachment), it appears that the DOV compound may also be useful at increasing weight loss.DOV causes a decrease in circulating triglycerides.The reason for weightloss is not going to be thermogenic or psychostimulant, or chronic decrease appetite. Read article for details.↑ 1.0 1.1 ↑ 2.0 2.1 ↑".
- DOV-216,303 atcPrefix "none".
- DOV-216,303 iupacName "1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane".
- DOV-216,303 pubchem "9795276".
- DOV-216,303 thumbnail DOV-216,303_structure.png?width=300.
- DOV-216,303 wikiPageID "22603947".
- DOV-216,303 wikiPageRevisionID "587616651".
- DOV-216,303 atcPrefix "none".
- DOV-216,303 c "11".
- DOV-216,303 cl "2".
- DOV-216,303 h "11".
- DOV-216,303 hasPhotoCollection DOV-216,303.
- DOV-216,303 iupacName "1".
- DOV-216,303 molecularWeight "228.117".
- DOV-216,303 n "1".
- DOV-216,303 pubchem "9795276".
- DOV-216,303 smiles "C3C2CNCC23cccc1Cl".
- DOV-216,303 verifiedrevid "402699925".
- DOV-216,303 width "160".
- DOV-216,303 subject Category:Organochlorides.
- DOV-216,303 subject Category:Pyrrolidines.
- DOV-216,303 subject Category:Serotonin-norepinephrine-dopamine_reuptake_inhibitors.
- DOV-216,303 type Drug.
- DOV-216,303 type DrugProduct.
- DOV-216,303 type FunctionalSubstance.
- DOV-216,303 comment "DOV 216,303 is an antidepressant drug originally developed by DOV Pharmaceutical and now licensed to the larger pharmaceutical company Merck & Co., which is currently in clinical trials. It is a so-called triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is expected to launch sometime around 2011. It is the racemic mixture of DOV 21,947 and its (–)-enantiomer. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.".
- DOV-216,303 label "DOV-216,303".
- DOV-216,303 sameAs m.05zzp04.
- DOV-216,303 sameAs Q5205904.
- DOV-216,303 sameAs Q5205904.
- DOV-216,303 wasDerivedFrom DOV-216,303?oldid=587616651.
- DOV-216,303 depiction DOV-216,303_structure.png.
- DOV-216,303 isPrimaryTopicOf DOV-216,303.